<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658082</url>
  </required_header>
  <id_info>
    <org_study_id>Sheba-19-6335-at-ctil</org_study_id>
    <nct_id>NCT04658082</nct_id>
  </id_info>
  <brief_title>A Pilot Trial to Evalute the Precision and Accuracy of the Non-invasive HGR Glucometer</brief_title>
  <official_title>A Pilot Trial to Evalute the Precision and Accuracy of the Non-invasive HGR Glucometer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Amir Tirosh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study evaluating the accuracty of a non-invasive glucose monitor (GWave) with venous&#xD;
      glucose measured by core laboratory during a glucose tolerance test (GTT) in patients with&#xD;
      type 2 diabetes.&#xD;
&#xD;
      The study is conducted on 5 subjects undergoing a 75gr GTT, with blood glucose measured at&#xD;
      baseline and at 8 time points up to 180 minutes post glucose ingestion both by GWave&#xD;
      non-invasive glucometer and by core lab glucose measurement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">November 16, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difference between core lab and non invasive glucose measurements</measure>
    <time_frame>3 HOURS</time_frame>
    <description>difference between core lab and non invasive glucose measurements</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Non invasive glucose monitor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single arm. All subjects will have glucose levels measured both by non invasive glucometer and by core lab</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>H.G.R (GWave) non-invasive glucometer</intervention_name>
    <description>Glucose tolerance test</description>
    <arm_group_label>Non invasive glucose monitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years and over with the diagnosis of Type 2 diabetes mellitus , HbA1c between&#xD;
             6.0-8.0% regardless of treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants under the age of 18 years, pregnant women or patients with normal blood&#xD;
             glucose).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Tirosh, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Prof. Amir Tirosh</investigator_full_name>
    <investigator_title>Director, Division of Endocrinology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

